The European Parliament has adopted the proposed amendment to the MDR to extend the transitional period for legacy Medical Devices.
关于作者
Navigate complex regulatory landscapes with expert guidance across pharmaceuticals, medical devices, and IVD.
Read more专家观点直达您的收件箱——选择您的兴趣。
绝无垃圾邮件。随时取消订阅。
Keep reading
Successful MedTech companies treat product development as a lifecycle strategy. Learn why regulatory planning, IP strategy and development must evolve together.
阅读更多
Developing Software as a Medical Device under EU MDR requires clear intended use, risk classification under Rule 11, and compliance with IEC 62304. Learn what SaMD developers need to know.
阅读更多
IP strategy should start early in MedTech development. Discover how patent strategy, regulatory classification, and product development influence IP protection for emerging MedTech companies.
阅读更多